Lexeo Therapeutics Inc (LXEO)

$7.25 -0.27 (-3.59%)
Market Cap 540.83M
Revenue (ttm) 0.00
Net Income (ttm) -98.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 664,302
Avg Vol 1,292,402
Day's Range N/A - N/A
Shares Out 72.99M
Stochastic %K 51%
Beta 1.75
Analysts Strong Sell
Price Target $19.64

Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 547 9879
Address:
345 Park Avenue South, 6th Floor, New York, United States
Aawilliam2003
Aawilliam2003 Feb. 4 at 5:43 PM
$LRMR this is not trading well. Who thinks they will get the nod to file in Q2? There are several other companies making waves in this space that may complicate their efforts eg $LXEO $SLDB
0 · Reply
CandleChief
CandleChief Feb. 4 at 4:07 PM
$LXEO is a technology or materials company; without specifics, analysis would focus on its product cycle, competitive position, and end-market demand.
0 · Reply
MacAwoo
MacAwoo Feb. 3 at 6:14 PM
$LXEO 🤔💭
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 22 at 1:55 PM
$LXEO RSI: 31.46, MACD: -0.6054 Vol: 1.29, MA20: 9.15, MA50: 9.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 22 at 12:24 AM
Largest changes in share price for XBI components since 1/9/2026 (pre-JP Morgan) for entertainment purposes only. The XBI is up 3% since the event started. $CRVS posted compelling Eczema/AD data this morning $IBRX is self-evident after the NSCLC data (coupled with Q425 sales). $ERAS ? $SPRY We did not see any new PR. ARS bounced back from the $7.00 lows around Thanksgiving. $LXEO Can any LXEO bull comment on the data? The 2020 data appeared OK We focus on commercial-stage so we're only trying to learn. This is not investment advice.
2 · Reply
Aawilliam2003
Aawilliam2003 Jan. 21 at 3:21 AM
$LXEO what's better for FA? LRMR or LXEO
1 · Reply
Bankstar
Bankstar Jan. 18 at 6:34 PM
$LXEO 👀
0 · Reply
MacAwoo
MacAwoo Jan. 16 at 9:51 PM
$LXEO might be time for some accumulation
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 16 at 9:20 PM
$LXEO Share Price: $7.40 Contract Selected: Aug 21, 2026 $5 Calls Buy Zone: $0.89 – $1.10 Target Zone: $1.58 – $1.93 Potential Upside: 67% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
xsiddiqmx
xsiddiqmx Jan. 13 at 10:57 PM
$LXEO closing gap nothing to see here. Up from here.
0 · Reply
Latest News on LXEO
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Jan 27, 2026, 7:30 AM EST - 8 days ago

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 1:56 PM EST - 21 days ago

Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

Jan 12, 2026, 12:55 PM EST - 23 days ago

Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Jan 12, 2026, 7:00 AM EST - 23 days ago

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 7:30 AM EST - 6 weeks ago

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

Dec 9, 2025, 5:57 PM EST - 2 months ago

Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Dec 4, 2025, 8:00 AM EST - 2 months ago

Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Lexeo Therapeutics: Behind The Rebound

Nov 6, 2025, 4:59 PM EST - 3 months ago

Lexeo Therapeutics: Behind The Rebound

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 5, 2025, 7:36 AM EST - 3 months ago

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Oct 20, 2025, 4:05 PM EDT - 3 months ago

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Oct 16, 2025, 11:29 PM EDT - 3 months ago

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Oct 16, 2025, 4:32 PM EDT - 3 months ago

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback

Oct 7, 2025, 3:22 PM EDT - 4 months ago

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback

Lexeo Therapeutics, Inc. - Special Call

Oct 7, 2025, 12:45 PM EDT - 4 months ago

Lexeo Therapeutics, Inc. - Special Call

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Oct 7, 2025, 6:00 AM EDT - 4 months ago

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Jul 7, 2025, 7:00 AM EDT - 7 months ago

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Jun 24, 2025, 7:30 AM EDT - 8 months ago

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 27, 2025, 7:31 AM EDT - 9 months ago

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 12, 2025, 7:00 AM EDT - 9 months ago

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

May 5, 2025, 2:19 PM EDT - 9 months ago

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

May 1, 2025, 9:16 AM EDT - 9 months ago

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Apr 7, 2025, 9:34 AM EDT - 10 months ago

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Apr 7, 2025, 6:00 AM EDT - 10 months ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 24, 2025, 7:00 AM EDT - 11 months ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 1 year ago

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Dec 19, 2024, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:30 AM EST - 1 year ago

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 30, 2024, 6:14 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Jul 16, 2024, 1:17 PM EDT - 1 year ago

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 12:05 PM EDT - 1 year ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Apr 9, 2024, 5:26 PM EDT - 1 year ago

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Mar 13, 2024, 4:22 PM EDT - 2 years ago

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 11, 2024, 7:42 AM EDT - 2 years ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Mar 11, 2024, 7:30 AM EDT - 2 years ago

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Feb 5, 2024, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Dec 18, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Dec 11, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

Nov 4, 2023, 12:21 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

ATGL HG IPO IPOS KVUE NCI PAPL

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Nov 3, 2023, 12:39 PM EDT - 2 years ago

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Oct 31, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Oct 2, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Aawilliam2003
Aawilliam2003 Feb. 4 at 5:43 PM
$LRMR this is not trading well. Who thinks they will get the nod to file in Q2? There are several other companies making waves in this space that may complicate their efforts eg $LXEO $SLDB
0 · Reply
CandleChief
CandleChief Feb. 4 at 4:07 PM
$LXEO is a technology or materials company; without specifics, analysis would focus on its product cycle, competitive position, and end-market demand.
0 · Reply
MacAwoo
MacAwoo Feb. 3 at 6:14 PM
$LXEO 🤔💭
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 22 at 1:55 PM
$LXEO RSI: 31.46, MACD: -0.6054 Vol: 1.29, MA20: 9.15, MA50: 9.25 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 22 at 12:24 AM
Largest changes in share price for XBI components since 1/9/2026 (pre-JP Morgan) for entertainment purposes only. The XBI is up 3% since the event started. $CRVS posted compelling Eczema/AD data this morning $IBRX is self-evident after the NSCLC data (coupled with Q425 sales). $ERAS ? $SPRY We did not see any new PR. ARS bounced back from the $7.00 lows around Thanksgiving. $LXEO Can any LXEO bull comment on the data? The 2020 data appeared OK We focus on commercial-stage so we're only trying to learn. This is not investment advice.
2 · Reply
Aawilliam2003
Aawilliam2003 Jan. 21 at 3:21 AM
$LXEO what's better for FA? LRMR or LXEO
1 · Reply
Bankstar
Bankstar Jan. 18 at 6:34 PM
$LXEO 👀
0 · Reply
MacAwoo
MacAwoo Jan. 16 at 9:51 PM
$LXEO might be time for some accumulation
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 16 at 9:20 PM
$LXEO Share Price: $7.40 Contract Selected: Aug 21, 2026 $5 Calls Buy Zone: $0.89 – $1.10 Target Zone: $1.58 – $1.93 Potential Upside: 67% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
xsiddiqmx
xsiddiqmx Jan. 13 at 10:57 PM
$LXEO closing gap nothing to see here. Up from here.
0 · Reply
VanRamirez937
VanRamirez937 Jan. 13 at 5:53 PM
$CCI $LXEO Yield theme evident
0 · Reply
Quantumup
Quantumup Jan. 13 at 12:20 PM
Oppenheimer reiterated $LXEO Outperform-$20 $RCKT $TNYA $LRMR $BIIB VYGR DSGN PTCT Oppenheimer said in its note: We believe yesterday's interim look from LX2020's Phase 1/2 HEROIC study in PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) yielded clear efficacy signals across the high-dose cohorts accompanied by unconcerning safety observations. With shares having closed down 23% vs. a flat XBI, the market may have been looking for a more consistent relationship between PKP2 increase and arrhythmia improvement-but we emphasize that the data remain immature, and look forward to 12-month follow-up results from all high-dose participants in 4Q26. We regard the selloff as having made the shares more attractive in view of LX2006's opportunity in Friedreich's ataxia ($1B+ US peak sales opportunity), which remains the key LXEO investor focus in our view and for which Phase 2 remains on track to begin in 1H.
1 · Reply
JavSuave
JavSuave Jan. 13 at 7:44 AM
$LXEO per Yahoo Finance
0 · Reply
lowriskdailycompounder
lowriskdailycompounder Jan. 12 at 11:00 PM
$LXEO
0 · Reply
mikelet
mikelet Jan. 12 at 10:10 PM
$LXEO Can somebody clarify if data is good or bad?
3 · Reply
Mamba2
Mamba2 Jan. 12 at 9:12 PM
$LXEO we got smoked on this. RIP
0 · Reply
stockanalysis_
stockanalysis_ Jan. 12 at 6:03 PM
Losers Today: $SDM $ATRA $LYRA $NBY $LXEO Save this screener to your bookmarks: https://stockanalysis.com/markets/losers/?ref=saveontrading
0 · Reply
garygb
garygb Jan. 12 at 3:17 PM
$LXEO Great entry point!
1 · Reply
Aagam447
Aagam447 Jan. 12 at 2:16 PM
$LXEO what went wrong??
1 · Reply
OpenOutcrier
OpenOutcrier Jan. 12 at 1:56 PM
$LXEO (-14.9% pre) Lexeo reports interim data for heart condition gene therapy https://ooc.bz/l/89382
0 · Reply
shukra_123
shukra_123 Jan. 12 at 12:58 PM
$LXEO https://ir.lexeotx.com/node/8731/pdf
0 · Reply
Thrasher5699
Thrasher5699 Jan. 9 at 7:16 PM
$LXEO Key 2026 Developments for LX2006 Trial Initiation: Lexeo plans to initiate the registrational (pivotal) study for LX2006 in the first half of 2026, pending finalization of the trial protocol with the FDA in early 2026. The actual start of this crucial trial would be a major positive catalyst for the stock, confirming the clinical path forward for its lead candidate. Regulatory Alignment: Finalization of the study protocol with the FDA is expected in early 2026. The company has already gained alignment with the FDA on key trial parameters, including using left ventricular mass index (LVMI) and frataxin expression as co-primary endpoints, which have shown promising results in earlier trials.
0 · Reply